# GLOW Peptide Benefits: What the Research Shows on GHK-Cu, BPC-157, and TB-500 > GLOW peptide benefits documented in the research literature: skin regeneration, wound healing, anti-fibrotic signaling, and hair follicle support from studies on the three constituent peptides. ## GLOW Peptide Benefits: What the Research Shows GLOW peptide benefits documented in the peer-reviewed literature come from studies on the three constituent peptides — GHK-Cu, BPC-157, and TB-500 — each studied individually in separate experimental settings. The combined GLOW formulation has not been tested in a controlled trial. The benefits below summarize the most robust findings from each constituent's research record, organized by the mechanism they address and the tissue or outcome type studied. ## GLOW peptide and skin repair research GHK-Cu within the GLOW blend has the most established skin-directed evidence of the three constituents. A 12-week clinical trial in 41 women showed that topical GHK-Cu increased procollagen synthesis in 70% of participants versus 50% for vitamin C and 40% for retinoic acid, reduced wrinkle depth by 32.8%, and improved skin density and thickness [1]. A 2024 comprehensive review confirmed these findings as representative of the human clinical data available, while identifying limited topical permeation (approximately 3.86% for unmodified GHK through synthetic skin) as the formulation challenge for topical application [7]. Subcutaneous administration bypasses this barrier. At the cellular level, GHK-Cu at 1–10 nanomolar concentrations upregulates collagen I and III synthesis, modulates matrix metalloproteinases (the enzymes that remodel existing collagen matrix), normalizes dermal fibroblast behavior in aged tissue, and activates antioxidant response elements [1,2]. A 2024 aged-fibroblast study found that GHK reversed the myofibroblast conversion pattern in primary lung fibroblasts from 24–26-month-old mice, restoring stemness markers and reducing senescence markers at statistical significance [3]. The anti-fibrotic effect on skin-adjacent fibroblast populations is mechanistically relevant to dermal repair. ## GHK-Cu and hair follicle research GHK-Cu has been studied for its role in stimulating hair follicle cell proliferation and maintenance. A 6-month randomized double-blind clinical trial in 45 men with androgenetic alopecia tested a topical formulation combining GHK-Cu with 5-aminolevulinic acid. Hair count increased by +52.6 hairs at the lower concentration and +71.5 hairs at the higher concentration after 6 months, compared to +9.6 hairs in the placebo group (p < 0.05); no adverse events were reported [4]. The proposed mechanism involves GHK-Cu's effects on Wnt/beta-catenin signaling in dermal papilla cells and its broader gene-expression effects on follicle maintenance genes — pathways consistent with the compound's wider regenerative profile. This is the only published human trial data on GHK-Cu and hair specifically; broader extrapolation to the GLOW blend for hair use is mechanistic inference, not direct trial evidence. ## Wound healing and tissue repair across the three constituents All three GLOW constituents have been independently studied for wound healing and tissue repair, each through distinct mechanisms. BPC-157 accelerated wound closure, improved granulation tissue maturity, and enhanced re-epithelialization across four wound types (incisional, excisional, deep burn, diabetic ulcer) in rats and small pigs at dose ranges spanning six orders of magnitude [11]. The effect was route-independent: intraperitoneal, oral, and topical administration all produced equivalent outcomes [11]. TB-500 increased wound reepithelialization by 42–61% at 4–7 days in rat full-thickness wound models and enhanced keratinocyte migration 2–3-fold in Boyden chamber assay at nanogram-to-picogram doses [17]. GHK-Cu at nanomolar concentrations accelerated fibroblast migration and collagen gel contraction in aged tissue models [3]. The wound-healing literatures for BPC-157 and TB-500 are the most directly comparable, both using animal wound models with measurable endpoints. GHK-Cu's wound-healing data comes primarily from in vitro models and clinical cosmetic studies. None of the three peptides has completed Phase III clinical trials for wound indications. ## Anti-fibrotic and anti-scarring research TB-500's most distinctive documented benefit is its anti-fibrotic activity through the Ac-SDKP metabolite pathway. Ac-SDKP — generated in vivo from thymosin beta-4 — prevents fibroblast-to-myofibroblast conversion, which is the cellular transition that turns normal wound healing into persistent fibrotic scarring. In animal models of liver, lung, heart, and kidney fibrosis, Ac-SDKP reversed established fibrosis, reduced macrophage infiltration, and decreased TGF-β and IL-10 levels [20]. GHK-Cu contributes through a parallel anti-fibrotic mechanism: it normalized myofibroblast senescence in aged lung fibroblasts, activating stemness markers and reducing p21/p53 senescence pathway activity [3]. BPC-157 showed context-dependent modulation of vascular response — pro-angiogenic in healing contexts but opposing pathological vascularization in injury contexts — which may contribute to limiting excessive vascular proliferation in the repair process [14]. ## GHK-Cu neuroprotective research GHK-Cu has been studied in aging mouse models for neuroprotective effects outside its better-known skin and wound literature. Intraperitoneal GHK at 7.5 mg/kg twice daily for five days prevented sleep-deprivation-induced learning impairment in 15-month-old female mice; treated animals performed comparably to non-sleep-deprived controls and showed decreased hippocampal MCP-1 and nitrotyrosine — markers of neuroinflammation and oxidative stress [5]. In a separate 8-week study, intranasal GHK-Cu at 15 mg/kg daily improved spatial memory and learning navigation in aged mice and reduced NFL-1 (an axonal damage marker) in both males and females [6]. These neuroprotective findings are from GHK-Cu studied in isolation in aged mouse models; they are not documented for BPC-157, TB-500, or the GLOW combination. Their relevance to the GLOW blend is indirect — they expand the studied biological activity of the GHK-Cu constituent. --- Three peptide literatures, one reading room — editorial summaries of peer-reviewed research, not clinical guidance.